Table 3.

Linear regression estimating relative risks of HPV and the vaccine, and HPV-associated HNC cancer knowledge.

	Adjusted β (95% CI)
	HPV & the Vaccine	HPV-associated HNC
Year of study
First Year	Ref	Ref
Second Year	2.62 (1.42, 3.82)	1.37 (0.78, 1.96)
Third Year	6.19 (4.96, 7.41)	1.84 (1.24, 2.45)
Fourth Year	6.75 (5.17, 8.33)	2.50 (1.72, 3.29)
Sex
Female	Ref	Ref
Male	-1.53 (−2.53, −0.52)	0.18 (−0.32, 0.68)
Race
White	Ref	Ref
Nonwhite	-1.05 (−2.07, −0.03)	-0.86 (−1.37, −0.36)
Marital status
Married	Ref	Ref
Single but Dating	0.28 (−1.05, 1.61)	0.16 (−0.50, 0.82)
Single and not Dating	−0.45 (−1.64, 0.74)	0.17 (−0.43, 0.76)
Number of oral sexual partners
None	Ref	Ref
One	0.51 (−1.11, 2.14)	0.61 (−0.20, 1.42)
≥Two	0.44 (−1.21, 2.08)	−0.04 (−0.85, 0.78)
Number of vaginal sexual partners
None	Ref	Ref
One	0.46 (−1.00, 1.93)	0.02 (−0.70, 0.75)
≥Two	<0.01 (−1.63, 1.63)	0.15 (−0.66, 0.96)
Specialty
Pediatrics	Ref	Ref
Family Medicine	−0.50 (−2.27, 1.28)	0.30 (−0.58, 1.18)
Internal Medicine	−0.46 (−1.91, 1.00)	<0.01 (−0.72, 0.72)
Surgery	−1.00 (−2.64, 0.63)	0.37 (−0.44, 1.18)
Other specialties	0.30 (−1.18, 1.79)	0.30 (−0.44, 1.04)

CI = Confidence Interval; HPV = Human Papillomavirus; HNC = Head and Neck Cancer.